No products in the cart.
Lparomlimab & Tuvonralimab Injection
$1.00
Lparomlimab & Tuvonralimab Injection Qibeian is a bi-functional monoclonal antibody combination developed by Qilu Pharmaceutical (QL1706), supplied as 50mg in 2mL vials. Approved by China’s NMPA (conditional marketing authorization No. S20240044; drug code 86904021005238). Intended exclusively for lab and investigative research applications, not for clinical or human use.
Description
Lparomlimab & Tuvonralimab Injection Product Specifications
| Attribute | Information |
|---|---|
| Product Name | Lparomlimab & Tuvonralimab Injection (Qibeian® / QL1706) |
| Formulation | Injection, 50mg in 2?mL vial |
| Approval No. | China NMPA S20240044 |
| Drug Standard Code | 86904021005238 |
| Manufacturer | Qilu Pharmaceutical Co., Ltd. |
| Intended Use | For research use only, not for therapeutic use |
Lparomlimab & Tuvonralimab Background & Mechanism
Qibeian (QL1706) combines two antibodies—lparomlimab (anti-PD?1) and tuvonralimab (anti-CTLA 4)—in a single product. This dual blockade enhances T-cell activation through simultaneous PD 1/CTLA 4 pathway inhibition
Conditionally approved by NMPA in September 2024 for recurrent/metastatic cervical cancer post-platinum therapy
Lparomlimab & Tuvonralimab Clinical Highlights
Phase II (DUBHE C 206): In recurrent/metastatic cervical cancer, objective response rate (ORR): 33.8%, disease control rate (DCR): 64.9%, median PFS: 5.4 months (148 patients)
Safety: 70.3% experienced treatment?related adverse events; 24.3% had grade ?3 TRAEs—most commonly anemia, thyroid dysfunction, GGT elevation
Research Applications
Ideal for preclinical and translational studies on:
Immune checkpoint inhibition
Tumor microenvironment research
Combination studies (e.g., with chemotherapy, targeted agents, radiotherapy)
Biomarker and pharmacodynamic assays
Storage & Handling
Storage: 2–8°C, avoid freezing.
Handling: Use aseptic technique in a biosafety cabinet.
Stability: Per manufacturer instructions (CCF refrigerated vials).
References
NMPA conditional approval announcement pubmed.ncbi.nlm.nih.gov+4english.nmpa.gov.cn+4english.nmpa.gov.cn+4
First approval review in Drugs journal biospace.com+15pubmed.ncbi.nlm.nih.gov+15bydrug.pharmcube.com+15
DUBHE C 206 Phase II trial data
Preclinical combination studies
Additional information
| Weight | 1.1 kg |
|---|---|
| Dimensions | 18 × 18 × 16 cm |
Related products
Rilertinib Mesylate Tablets (Sanrisso) – 100mg
Rilertinib mesylate (Sanrisso), developed by Nanjing Sanhome Pharmaceutical Co., Ltd., is a third-generation EGFR-TKI approved by China's NMPA (Approval No. H20240020; Drug Code: 86901583000930). Each bottle contains 20 tablets of 100mg each. Strictly for laboratory research use only—not for clinical or human use. $1.00Palbociclib Capsules (Xipeilai)
Palbociclib Capsules (Research Grade) in 125mg strength, 21-count bottle. Supplied by Shanghai Chuannuo Pharmaceutical Co., Ltd. For investigational or research applications only—not for human consumption or therapeutic use.
$2.00Mechlorethamine Hydrochloride Injection
Mechlorethamine hydrochloride (HaiPu®) is a potent DNA-alkylating agent from the nitrogen mustard class, supplied as a 1mL vial containing 5mg. Manufactured by Shanghai Xudong Haipu Pharmaceutical Co., Ltd., with NMPA approval H31020897 and product code 86900808000625. Strictly for laboratory research use.Please consult the staff for other purposes. $1.00Aprepitant Capsules
Aprepitant Capsules (Kangrenping), 125mg ×1 + 80mg ×2 per box. For laboratory research use only $1.00
Reviews
There are no reviews yet.